Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampProtagonist Therapeutics, Inc.Xenon Pharmaceuticals Inc.
Wednesday, January 1, 201418600005496000
Thursday, January 1, 201529630009786000
Friday, January 1, 201669610006792000
Sunday, January 1, 2017117790007313000
Monday, January 1, 2018136970008382000
Tuesday, January 1, 20191574900010803000
Wednesday, January 1, 20201863800012944000
Friday, January 1, 20212719600021967000
Saturday, January 1, 20223173900032810000
Sunday, January 1, 20233349100046542000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Xenon Pharmaceuticals Inc. and Protagonist Therapeutics, Inc. from 2014 to 2023. Over this period, both companies have shown a significant increase in their SG&A expenses, reflecting their growth and expansion strategies.

Key Insights

  • Protagonist Therapeutics, Inc.: Starting with modest expenses in 2014, Protagonist saw a dramatic rise, peaking in 2023 with a 1,700% increase from their initial figures.
  • Xenon Pharmaceuticals Inc.: Similarly, Xenon experienced a substantial growth in expenses, with a 750% increase over the same period.

This upward trend in SG&A expenses highlights the aggressive investment in research, development, and market expansion by both companies, positioning them as formidable players in the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025